AU2018230429B2 - Use of glucocorticoid receptor modulators in the treatment of catecholamine-secreting tumors - Google Patents

Use of glucocorticoid receptor modulators in the treatment of catecholamine-secreting tumors Download PDF

Info

Publication number
AU2018230429B2
AU2018230429B2 AU2018230429A AU2018230429A AU2018230429B2 AU 2018230429 B2 AU2018230429 B2 AU 2018230429B2 AU 2018230429 A AU2018230429 A AU 2018230429A AU 2018230429 A AU2018230429 A AU 2018230429A AU 2018230429 B2 AU2018230429 B2 AU 2018230429B2
Authority
AU
Australia
Prior art keywords
catecholamine
patient
gra
treatment
glucocorticoid receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018230429A
Other languages
English (en)
Other versions
AU2018230429A1 (en
Inventor
Andreas G. MORAITIS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Corcept Therapeutics Inc
Original Assignee
Corcept Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corcept Therapeutics Inc filed Critical Corcept Therapeutics Inc
Publication of AU2018230429A1 publication Critical patent/AU2018230429A1/en
Application granted granted Critical
Publication of AU2018230429B2 publication Critical patent/AU2018230429B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
AU2018230429A 2017-03-09 2018-03-08 Use of glucocorticoid receptor modulators in the treatment of catecholamine-secreting tumors Active AU2018230429B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762469296P 2017-03-09 2017-03-09
US62/469,296 2017-03-09
PCT/US2018/021592 WO2018165460A1 (en) 2017-03-09 2018-03-08 Use of glucocorticoid receptor modulators in the treatment of catecholamine-secreting tumors

Publications (2)

Publication Number Publication Date
AU2018230429A1 AU2018230429A1 (en) 2019-09-05
AU2018230429B2 true AU2018230429B2 (en) 2023-06-15

Family

ID=63446773

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018230429A Active AU2018230429B2 (en) 2017-03-09 2018-03-08 Use of glucocorticoid receptor modulators in the treatment of catecholamine-secreting tumors

Country Status (8)

Country Link
US (1) US11045482B2 (enExample)
EP (1) EP3592358A4 (enExample)
JP (3) JP7564620B2 (enExample)
CN (1) CN110475558A (enExample)
AU (1) AU2018230429B2 (enExample)
CA (1) CA3053806A1 (enExample)
MX (1) MX2019010732A (enExample)
WO (1) WO2018165460A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020132171A1 (en) * 2018-12-20 2020-06-25 Corcept Therapeutics Incorporated Methods for imaging and treatment of somatostatin-receptor positive tumors
JP2021079146A (ja) * 2021-02-22 2021-05-27 株式会社三洋物産 遊技機
JP7315071B2 (ja) * 2021-03-03 2023-07-26 株式会社三洋物産 遊技機

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009050136A2 (en) * 2007-10-17 2009-04-23 Laboratoire Hra Pharma Glucocorticoid receptor antagonists such as mifepristone for treating cushing' s syndrome
WO2013039916A1 (en) * 2011-09-12 2013-03-21 The United States Of America, Represented By The Secretary, Dept. Of Health And Human Services Compositions for and methods of treatment and enhanced detection of non-pituitary tumors
WO2016140867A1 (en) * 2015-03-02 2016-09-09 Corcept Therapeutics, Inc. Use of glucocorticoid receptor antagonist and somatostatin analogues to treat acth-secreting tumors

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9606736D0 (en) 1996-02-19 1996-06-05 Shire International Licensing Therapeutic method
CA2246791A1 (en) 1998-09-01 2000-03-01 Alison Buchan Treatment of endothelium with somatostatin analogues
US6818739B2 (en) 1999-12-03 2004-11-16 Ndsu Research Foundation Somatostatins
US6139845A (en) 1999-12-07 2000-10-31 Allergan Sales, Inc. Method for treating cancer with a neurotoxin
CN1556709A (zh) * 2001-03-23 2004-12-22 �Ƹ��� 使用糖皮质激素受体特效拮抗剂治疗压力症的方法
WO2003057214A1 (en) 2001-12-28 2003-07-17 Somatocor Pharmaceuticals, Inc. Imidazolidin-2,4-dione derivatives as non-peptide somatostatin receptor ligands
ATE407934T1 (de) 2004-03-09 2008-09-15 Corcept Therapeutics Inc Azadecalinverbindungen mit kondensiertem ring als glucocorticoidrezeptormodulatoren
GB0428151D0 (en) * 2004-12-22 2005-01-26 Novartis Ag Organic compounds
EP2145186A4 (en) * 2007-05-15 2010-10-20 Water Technologies Corp APPARATUS AND METHODS FOR DETECTION OF PLASMA METANEPHRINS
ES2351569B8 (es) 2009-05-07 2012-06-20 Bcn Peptides S.A. Ligandos peptídicos de receptores de somatostatina.
EP2429529B1 (en) 2009-05-12 2015-01-14 Corcept Therapeutics, Inc. Solid forms and process for preparing
AU2011213557B2 (en) * 2010-02-05 2015-05-07 Phosphagenics Limited Carrier comprising non-neutralised tocopheryl phosphate
KR101925955B1 (ko) 2011-03-18 2018-12-06 코어셉트 쎄라퓨틱스, 잉크. 피리미딘 사이클로헥실 글루코코르티코이드 수용체 조절제
US8859774B2 (en) 2012-05-25 2014-10-14 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
RU2674983C1 (ru) 2013-11-25 2018-12-14 Корсепт Терапеутикс, Инк. Октагидро конденсированные азадекалиновые модуляторы глюкокортикоидного рецептора
US9943526B2 (en) * 2015-04-21 2018-04-17 Corcept Therapeutics, Inc. Optimizing mifepristone levels for cushing's patients

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009050136A2 (en) * 2007-10-17 2009-04-23 Laboratoire Hra Pharma Glucocorticoid receptor antagonists such as mifepristone for treating cushing' s syndrome
WO2013039916A1 (en) * 2011-09-12 2013-03-21 The United States Of America, Represented By The Secretary, Dept. Of Health And Human Services Compositions for and methods of treatment and enhanced detection of non-pituitary tumors
WO2016140867A1 (en) * 2015-03-02 2016-09-09 Corcept Therapeutics, Inc. Use of glucocorticoid receptor antagonist and somatostatin analogues to treat acth-secreting tumors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DE BRUIN, C. et al. The Journal of Clinical Endocrinology & Metabolism (2012) Vol.97 Issue 2, pages 455 to 462 *
SARTOR O; CUTLER JR G B: "Mifepristone: Treatment of Cushing's syndrome", CLINICAL OBSTETRICS AND GYNECOLOGY., HARPER AND ROW, HAGERSTOWN, MD., US, vol. 39, no. 2, 1 January 1996 (1996-01-01), US , pages 506 - 510, XP009184753, ISSN: 0009-9201, DOI: 10.1097/00003081-199606000-00024 *

Also Published As

Publication number Publication date
JP2024074854A (ja) 2024-05-31
MX2019010732A (es) 2019-11-01
WO2018165460A1 (en) 2018-09-13
JP2022090003A (ja) 2022-06-16
EP3592358A1 (en) 2020-01-15
JP2020510011A (ja) 2020-04-02
US20180256604A1 (en) 2018-09-13
CA3053806A1 (en) 2018-09-13
EP3592358A4 (en) 2020-12-16
US11045482B2 (en) 2021-06-29
JP7564620B2 (ja) 2024-10-09
CN110475558A (zh) 2019-11-19
AU2018230429A1 (en) 2019-09-05

Similar Documents

Publication Publication Date Title
CA3034114C (en) Glucocorticoid receptor modulators to treat pancreatic cancer
US11073523B2 (en) Method for differentially diagnosing ACTH-dependent Cushing's syndrome
AU2016226451B2 (en) Use of glucocorticoid receptor antagonist and somatostatin analogues to treat ACTH-secreting tumors
JP2024074854A (ja) カテコールアミン分泌腫瘍の処置における糖質コルチイド受容体モジレータの使用
BR112021015129A2 (pt) Método para tratar um paciente que sofre de hipercortisolemia e um sintoma ou comorbidade da mesma
CA2728563C (en) Use of mifepristone for the treatment of amyotrophic lateral sclerosis
JP7670462B2 (ja) 選択的グルココルチコイドレセプターモジュレーターを使用して神経上皮腫瘍を処置する方法
CA2978960C (en) Use of glucocorticoid receptor antagonists in combination with glucocorticoids to treat adrenal insufficiency
JP2020509032A (ja) 糖質コルチコイド受容体モジュレータおよびｃｙｐ３ａインヒビタの併用投与
WO2009021022A2 (en) Modulating the activity of nuclear receptors in order to treat hypoxia-related disorders
AU2023334046A1 (en) Methods of treating prostate cancer using exicorilant and enzalutamide
HK1255714B (en) Method for differentially diagnosing acth-dependent cushing's syndrome

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)